Various studies have identified the association between CSCs and a shorter progression-free interval and worse prognosis in ovarian cancer[55,56], including a recent meta-analysis study that examined the correlation between four representative ovarian CSC marker candidates ALDH1/CD44/CD117/CD133 and prognosis[57]. This evidence concerns the gene KIT and ovarian carcinoma.